ArticleArchives of toxicology2026
Early metabolic rewiring precedes arsenic-induced carcinogenesis in human lung epithelial cells.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Chronic, low-dose inorganic arsenic (iAs) exposure is a major environmental risk factor for lung cancer, yet the early cellular events that link low-dose exposure to carcinogenesis remain poorly understood. Because most people are exposed to iAs at low, chronic doses rather than acutely toxic levels, the metabolic events during this early window are especially relevant to human cancer risk. In this study, we investigated metabolic responses to non-cytotoxic, low-dose iAs exposure (0.5-2.0 µM) in human lung epithelial cells using short (48 h) and long (24-week) exposure models. Integrated transcriptomic and metabolomic analyses revealed that metabolic reprogramming begins within 48 h of exposure, characterized by increased glutathione synthesis, increased glycolysis, and triglyceride accumulation. The early adaptations mirrored the Warburg effect and dynamic lipid remodeling we observed in our chronic model of iAs exposure (0.5 µM). These findings indicate that iAs induces early metabolic rewiring that precedes cell transformation in human lung cells and suggest that low-dose iAs exposure may metabolically prime cells to support later oncogenic events and phenotypes. Metabolic networks underpinning the cellular response to iAs may therefore provide therapeutic targets for preventing or treating iAs-induced lung cancers.
Indexed as
Identifiers
42800834What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.